Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Authors
Keywords
Cisplatin, Drug resistance, Ovarian cancer, Targeted therapy, Phytochemicals, New agents, Combination therapy
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 232, Issue -, Pages 114205
Publisher
Elsevier BV
Online
2022-02-17
DOI
10.1016/j.ejmech.2022.114205
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- (2021) Deborah K. Armstrong et al. Journal of the National Comprehensive Cancer Network
- Advances in epigenetic therapeutics with focus on solid tumors
- (2021) Ning Jin et al. Clinical Epigenetics
- Tumor hypoxia: The major culprit behind cisplatin resistance in cancer patients
- (2021) Nalini Devarajan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- 1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study
- (2021) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
- (2021) Kristie-Ann Dickson et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
- (2021) Chunfeng Xie et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Extracellular vesicles as a next-generation drug delivery platform
- (2021) Inge Katrin Herrmann et al. Nature Nanotechnology
- Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells
- (2021) Jerneja Kladnik et al. Cancers
- Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer
- (2021) Amal A. Al-Dossary et al. Cancers
- Palladium(II)‐η3‐allyl complexes bearing N‐trifluoromethyl N‐heterocyclic carbenes:a new generation of anticancer agents which restrain the growth of high grade serous ovarian cancer tumoroids
- (2020) Fabiano Visentin et al. CHEMISTRY-A EUROPEAN JOURNAL
- In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target
- (2020) Mauro Carcelli et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
- (2020) L.R. Duska et al. GYNECOLOGIC ONCOLOGY
- The development of a homologous recombination deficiency (HRD) score to identify HR-deficient tumors.
- (2020) Xiaohua Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer
- (2020) Qingfei Zhang et al. NANO LETTERS
- Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining
- (2020) Haixia Li et al. Journal of Ovarian Research
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells
- (2020) Xiaohui Zhang et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Extracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials
- (2020) Akiko Kogure et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma
- (2020) Ke Gong et al. International Journal of Nanomedicine
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest
- (2020) Michael Tsabar et al. Cell Reports
- Epigenetics and epigenomics: underlying mechanisms, relevance, and implications in crop improvement
- (2020) Gaurav Agarwal et al. FUNCTIONAL & INTEGRATIVE GENOMICS
- Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer
- (2020) L. Loverix et al. GYNECOLOGIC ONCOLOGY
- Facile synthesis of heterobimetallic [FeII(µ-diphosphine)RuII] and homobimetallic [FeII(µ-diphosphine)FeII] complexes and their in vitro cytotoxic activity on cisplatin-resistant cancer cells
- (2020) Danya BenYosef et al. INORGANICA CHIMICA ACTA
- Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models
- (2020) Safiah Ibrahim Althurwi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nanoparticle delivery systems to combat drug resistance in ovarian cancer
- (2020) Emily M. Miller et al. Nanomedicine-Nanotechnology Biology and Medicine
- High Expression of Nuclear Transcription Factor-κB is Associated with Cisplatin Resistance and Prognosis for Ovarian Cancer
- (2020) Yanyan Kan et al. Cancer Management and Research
- Role of Nucleotide Excision Repair in Cisplatin Resistance
- (2020) Mingrui Duan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake
- (2019) Xiaoxue Lv et al. MOLECULAR CARCINOGENESIS
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer
- (2019) Christopher Halbur et al. SLAS Technology
- BCL-2 family isoforms in apoptosis and cancer
- (2019) Chloe F. A. Warren et al. Cell Death & Disease
- pH-Responsive Polymer Nanoparticles for Drug Delivery
- (2019) Nayeleh Deirram et al. MACROMOLECULAR RAPID COMMUNICATIONS
- Recent advances in polymer-based drug delivery systems for local anesthetics
- (2019) Bo Wang et al. Acta Biomaterialia
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives
- (2019) Muhammad Altaf et al. Cancers
- Cisplatin: The first metal based anticancer drug
- (2019) Sumit Ghosh BIOORGANIC CHEMISTRY
- Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
- (2019) E. Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
- (2019) E. Zsiros et al. GYNECOLOGIC ONCOLOGY
- β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer
- (2019) Piera Tocci et al. Nature Communications
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
- (2019) Shang-Hung Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
- (2019) Shahin Aghamiri et al. Nanomedicine
- Structural basis of homologous recombination
- (2019) Yueru Sun et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Ligand-Controlled Reactivity and Cytotoxicity of Cyclometalated Rhodium(III) Complexes
- (2019) Wen-Ying Zhang et al. EUROPEAN JOURNAL OF INORGANIC CHEMISTRY
- Ovarian damage from chemotherapy and current approaches to its protection
- (2019) N Spears et al. HUMAN REPRODUCTION UPDATE
- New findings on the antiproliferative activity of the silver(I) complex with 5-fluorouracil against human multi-resistant NCI/ADR-RES ovarian tumor cells
- (2019) Julia H. Bormio Nunes et al. TOXICOLOGY IN VITRO
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- Thiourea and Guanidine Compounds and Their Iridium Complexes in Drug‐Resistant Cancer Cell Lines: Structure‐Activity Relationships and Direct Luminescent Imaging
- (2019) Samuel J. Thomas et al. ChemMedChem
- Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study
- (2019) Kurtulus Gokduman Nanomedicine
- Anticancer platinum-based complexes with non-classical structures
- (2018) Linxiang Cai et al. APPLIED ORGANOMETALLIC CHEMISTRY
- MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B
- (2018) Fang Xiao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation
- (2018) Si Sun et al. CANCER SCIENCE
- A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
- (2018) Mingming Miao et al. GYNECOLOGIC ONCOLOGY
- Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells
- (2018) Haibo Pan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Scutellaria baicalensis targets the hypoxia-inducible factor-1α and enhances cisplatin efficacy in ovarian cancer
- (2018) Imran Hussain et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Molecular mechanisms of drug resistance in ovarian cancer
- (2018) Leyla Norouzi-Barough et al. JOURNAL OF CELLULAR PHYSIOLOGY
- siRNA in ovarian cancer – Delivery strategies and targets for therapy
- (2018) Dirk van den Brand et al. JOURNAL OF CONTROLLED RELEASE
- Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
- (2018) Sophia A. Shahin et al. Nanomedicine-Nanotechnology Biology and Medicine
- Exosome: Function and Role in Cancer Metastasis and Drug Resistance
- (2018) Chengcheng Zhang et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- FABP4 as a key determinant of metastatic potential of ovarian cancer
- (2018) Kshipra M. Gharpure et al. Nature Communications
- PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
- (2018) Chitra Risnayanti et al. Scientific Reports
- PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs
- (2018) Tabassum Khan et al. Frontiers in Pharmacology
- Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
- (2018) Chun-Yan Lan et al. LANCET ONCOLOGY
- Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Radoslav Chekerov et al. LANCET ONCOLOGY
- PARP INHIBITION IN PLATINUM-BASED CHEMOTHERAPY: CHEMOPOTENTIATION AND NEUROPROTECTION
- (2018) Rachel M McQuade et al. PHARMACOLOGICAL RESEARCH
- Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
- (2018) Reema Narayan et al. Pharmaceutics
- 944PQUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset
- (2018) K N Moore et al. ANNALS OF ONCOLOGY
- Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
- (2018) Xuejiao Li et al. BIOINORGANIC CHEMISTRY AND APPLICATIONS
- The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation
- (2018) Hao Wang et al. Cell Death & Disease
- Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion
- (2018) Haixia Wang et al. Journal of Ovarian Research
- Immune Checkpoints as Therapeutic Targets in Autoimmunity
- (2018) Christopher Paluch et al. Frontiers in Immunology
- Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds
- (2018) Kirill Gorshkov et al. Translational Oncology
- Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein
- (2018) Brian Kawahara et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies
- (2017) Federica Tomao et al. EXPERT OPINION ON PHARMACOTHERAPY
- Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
- (2017) Roberto Sorio et al. GYNECOLOGIC ONCOLOGY
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
- (2017) Mohamed Wehbe et al. INVESTIGATIONAL NEW DRUGS
- Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
- (2017) Seung Min Kim et al. JOURNAL OF CONTROLLED RELEASE
- Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer
- (2017) Yakup Bozkaya et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Liposome-based drug co-delivery systems in cancer cells
- (2017) Sepideh Zununi Vahed et al. Materials Science & Engineering C-Materials for Biological Applications
- Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models
- (2017) Cai M. Roberts et al. Nanomedicine-Nanotechnology Biology and Medicine
- Saikosaponin-d, a calcium mobilizing agent, sensitizes chemoresistant ovarian cancer cells to cisplatin-induced apoptosis by facilitating mitochondrial fission and G2/M arrest
- (2017) Hideaki Tsuyoshi et al. Oncotarget
- Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer
- (2017) Jia Liu et al. Oncotarget
- Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer
- (2017) Magdalena Ratajska et al. Oncotarget
- Exosomes as mediators of platinum resistance in ovarian cancer
- (2017) Jennifer Crow et al. Oncotarget
- Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
- (2016) F. Trillsch et al. ANNALS OF ONCOLOGY
- Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
- (2016) Nazila Kamaly et al. CHEMICAL REVIEWS
- Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
- (2016) Zbynek Heger et al. CURRENT DRUG TARGETS
- ABC transporters as mediators of drug resistance and contributors to cancer cell biology
- (2016) Jamie I. Fletcher et al. DRUG RESISTANCE UPDATES
- Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer
- (2016) Jun Liang et al. GYNECOLOGIC AND OBSTETRIC INVESTIGATION
- Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
- (2016) Susan M. Domchek et al. GYNECOLOGIC ONCOLOGY
- Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
- (2016) Bowen Du et al. MOLECULES
- Nanostructured lipid carriers: Promising drug delivery systems for future clinics
- (2016) Ana Beloqui et al. Nanomedicine-Nanotechnology Biology and Medicine
- Cisplatin resistance and opportunities for precision medicine
- (2016) Lauren Amable PHARMACOLOGICAL RESEARCH
- Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems
- (2016) Jafar Ezzati Nazhad Dolatabadi et al. TRAC-TRENDS IN ANALYTICAL CHEMISTRY
- The functions and clinical applications of tumor-derived exosomes
- (2016) Yingkuan Shao et al. Oncotarget
- Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer
- (2015) Chunbai He et al. BIOMATERIALS
- The development of PARP inhibitors in ovarian cancer: from bench to bedside
- (2015) Yvette Drew BRITISH JOURNAL OF CANCER
- Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway
- (2015) Qiaoyun Chen et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The role of ABC transporters in ovarian cancer progression and chemoresistance
- (2015) M.P. Ween et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Nucleotide excision repair in humans
- (2015) Graciela Spivak DNA REPAIR
- 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity
- (2015) M.L. Disis et al. EUROPEAN JOURNAL OF CANCER
- Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy
- (2015) Helen HW Chen et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells
- (2015) Ryan Charles Pink et al. GYNECOLOGIC ONCOLOGY
- Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy
- (2015) MICHAL PASTOREK et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway
- (2015) HAIZHI HUANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells
- (2015) YIFEI WANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex
- (2015) Jong-Hwan Lee et al. JOURNAL OF CONTROLLED RELEASE
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Current status and future directions of anti-angiogenic therapy for gliomas
- (2015) Wolfgang Wick et al. NEURO-ONCOLOGY
- Broad targeting of resistance to apoptosis in cancer
- (2015) Ramzi M. Mohammad et al. SEMINARS IN CANCER BIOLOGY
- Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
- (2015) Andrew J. Wilson et al. Journal of Ovarian Research
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
- (2014) Juan Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Emodin Augments Cisplatin Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells via ROS-Dependent MRP1 Downregulation
- (2014) Jun Ma et al. Biomed Research International
- Ovarian cancer stem cells: Are they real and why are they important?
- (2013) Monjri M. Shah et al. GYNECOLOGIC ONCOLOGY
- β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK
- (2013) QUENTIN Q. LI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The Diarylheptanoid Hirsutenone Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin via Modulation of Apoptosis-inducing Factor and X-linked Inhibitor of Apoptosis
- (2013) Lee Farrand et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- (2013) Emma L. Barber et al. Journal of Gynecologic Oncology
- EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
- (2012) Alexandria M Haslehurst et al. BMC CANCER
- Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum
- (2012) Julie A. DeLoia et al. GYNECOLOGIC ONCOLOGY
- Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cellsin vivo
- (2012) Sutapa Sinha et al. INTERNATIONAL JOURNAL OF CANCER
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
- (2012) C Zeller et al. ONCOGENE
- Various modes of cell death induced by DNA damage
- (2012) O Surova et al. ONCOGENE
- Subcellular targets of cisplatin cytotoxicity: An integrated view
- (2012) Sandra M. Sancho-Martínez et al. PHARMACOLOGY & THERAPEUTICS
- Delivery of chemotherapeutic drugs in tumour cell-derived microparticles
- (2012) Ke Tang et al. Nature Communications
- Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo
- (2011) Yuxing Zhang et al. CANCER LETTERS
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- The status of platinum anticancer drugs in the clinic and in clinical trials
- (2010) Nial J. Wheate et al. DALTON TRANSACTIONS
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro
- (2010) Michaela L. Krieger et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2010) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77Å resolution
- (2010) Ryan C. Todd et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Regulation of Copper Transporter 2 Expression by Copper and Cisplatin in Human Ovarian Carcinoma Cells
- (2010) B. G. Blair et al. MOLECULAR PHARMACOLOGY
- Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian Cells
- (2010) Christopher Hom et al. Small
- Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth
- (2010) Murali M Yallapu et al. Journal of Ovarian Research
- Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
- (2009) Rosaria Gangemi et al. CURRENT MEDICINAL CHEMISTRY
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Platinum Resistance: The Role of DNA Repair Pathways
- (2008) L. P. Martin et al. CLINICAL CANCER RESEARCH
- Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB
- (2008) Leigh A Solomon et al. Journal of Ovarian Research
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started